Irritable bowel syndrome - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Irritable bowel syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable bowel syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Irritable bowel syndrome: Overview
Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. With IBS, you have these symptoms without any visible signs of damage or disease in your digestive tract. The most common symptoms of irritable bowel syndrome (IBS) are pain in your abdomen, often related to your bowel movements, and changes in your bowel movements. These changes may be diarrhea, constipation, or both, depending on what type of IBS you have. To diagnose irritable bowel syndrome (IBS), doctors review the symptoms and the medical and family history and perform a physical exam. The doctor will look for a certain pattern in the symptoms. In some cases, doctors may order tests to rule out other health problems.
'Irritable bowel syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Irritable bowel syndrome pipeline landscape is provided which includes the disease overview and Irritable bowel syndrome treatment guidelines. The assessment part of the report embraces, in depth Irritable bowel syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Irritable bowel syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Irritable bowel syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Irritable bowel syndrome Emerging Drugs
Further product details are provided in the report
Irritable bowel syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Irritable bowel syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Irritable bowel syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Irritable bowel syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Irritable bowel syndrome drugs.
Irritable bowel syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Irritable bowel syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Irritable bowel syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Irritable bowel syndrome: Overview
Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. With IBS, you have these symptoms without any visible signs of damage or disease in your digestive tract. The most common symptoms of irritable bowel syndrome (IBS) are pain in your abdomen, often related to your bowel movements, and changes in your bowel movements. These changes may be diarrhea, constipation, or both, depending on what type of IBS you have. To diagnose irritable bowel syndrome (IBS), doctors review the symptoms and the medical and family history and perform a physical exam. The doctor will look for a certain pattern in the symptoms. In some cases, doctors may order tests to rule out other health problems.
'Irritable bowel syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Irritable bowel syndrome pipeline landscape is provided which includes the disease overview and Irritable bowel syndrome treatment guidelines. The assessment part of the report embraces, in depth Irritable bowel syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Irritable bowel syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Irritable bowel syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Irritable bowel syndrome.
This segment of the Irritable bowel syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Irritable bowel syndrome Emerging Drugs
- Olorinab: Arena Pharmaceuticals
- Blautix: 4D Pharma
Further product details are provided in the report
Irritable bowel syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Irritable bowel syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Irritable bowel syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Irritable bowel syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Irritable bowel syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Irritable bowel syndrome drugs.
Irritable bowel syndrome Report Insights
- Irritable bowel syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Irritable bowel syndrome drugs?
- How many Irritable bowel syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Irritable bowel syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Irritable bowel syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Irritable bowel syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Arena Pharmaceuticals
- 4D Pharma
- OrphoMed
- Boston Pharmaceuticals
- RedHill Biopharma Limited
- Takeda
- Cosmo Technologies
- CinRx Pharma
- Rottapharm
- SK biopharmaceuticals
- Synthetic Biologics
- Biomica
- Dong-A ST Co Ltd
- Metacrine
- MGC Pharma
- Napo Pharmaceuticals
- Nobilis Therapeutics
- Novome Biotechnologies
- RQ-00310941
- Renexxion
- Sentia Medical Sciences
- Serentrix LLC
- Velicept Therapeutics
- Vitality Biopharma
- Oxford Cannabinoid Technologies
- Olorinab
- Blautix
- ORP-101
- BOS-589
- BEKINDA
- Mesalamine
- Rifamycin controlled-release
- CIN 103
- Dexloxiglumide
- Relenopride
- Lovastatin modified release
- BMC426
- DA-6886
- MET409
- Crofelemer
- NBTX-001
- RQ-00310941
- Ser-224
- Velicept
- VBX-100
- AAT 730
Introduction
Executive Summary
Irritable bowel syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Irritable bowel syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Irritable bowel syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Irritable bowel syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Olorinab: Arena Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
MET409: Metacrine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Irritable bowel syndrome Key Companies
Irritable bowel syndrome Key Products
Irritable bowel syndrome- Unmet Needs
Irritable bowel syndrome- Market Drivers and Barriers
Irritable bowel syndrome- Future Perspectives and Conclusion
Irritable bowel syndrome Analyst Views
Irritable bowel syndrome Key Companies
Appendix
Executive Summary
Irritable bowel syndrome: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Irritable bowel syndrome – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Irritable bowel syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Irritable bowel syndrome Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Olorinab: Arena Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
MET409: Metacrine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Irritable bowel syndrome Key Companies
Irritable bowel syndrome Key Products
Irritable bowel syndrome- Unmet Needs
Irritable bowel syndrome- Market Drivers and Barriers
Irritable bowel syndrome- Future Perspectives and Conclusion
Irritable bowel syndrome Analyst Views
Irritable bowel syndrome Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Irritable bowel syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Irritable bowel syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Irritable bowel syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Irritable bowel syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products